New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene -; a mutation also responsible for some types of melanoma, colorectal cancer, leukemia, lymphoma, and ovarian cancer.
Research discovers fibronectin’s role in BRAF-mutant thyroid cancer resistance
- Post author:
- Post published:January 10, 2024
- Post category:uncategorized